Week of June 17th, 2019 | FDA Sent These Warning Letters to Pharma/Device Companies

Unlike last week, warning letter enforcement is sparse this week with only one drug GMP warning letter, none to compounding pharmacies and none to device firms.

 

Be a leader in GMP intelligence.
Get our weekly regulatory newsletters free for a month.

 


DRUGS | Tropical Seas, Inc

Tropical Seas, Inc (Holly Hill, FL) received a warning letter on May 15, 2019, based on the outcome of an inspection ending May 30, 3018.  The firm manufactures OTC products.

Deficiencies include but are not limited to:

  • The firm does not consistently perform growth promotion testing on the in-house media used for microbial testing.  When performed, the practice is not documented.
  • The firm did not adequately investigate a customer complaint, nor did they consider extending this investigation to consider other batches.  This is a repeat observation from a 2015 inspection.
  • It isn’t clear how the firm addresses whether the glycerin they use in manufacture is free from ethylene glycol contamination.
  • The firm cannot provide evidence that their UV test method is equivalent to the USP method. This represents another repeat observation from the 2015 inspection.
  • The firm is also cited for distributing unapproved new drugs and misbranding of drugs — lots of examples here of problematic advertising descriptions on their website.

 

Like this & want more?
Sign up to get free weekly content updates
designed to make your job easier
.

 

Learn more about how FDAzilla can help you achieve your quality and inspection preparation goals: get 483sInspectorProfilesEnforcement Analytics, and GMP Regulatory Intelligence. Contact us if you ever have questions at sales@fdazilla.com.

Like this post? Don't forget to share it!

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Recent Posts

Experience the Power of FDAzilla

Get your FREE account to search sites, inspections, & warning letters